Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
NEW YORK, Dec. 22, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Alexion Pharmaceuticals, Inc. securities (NASDAQ:ALXN) from February 10, 2014 through November 9, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Alexion investors under the federal securities laws.
To join the Alexion class action, go to http://rosenlegal.com/cases-991.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Alexion employed improper sales practices with respect to Soliris; (2) consequently, Alexion’s revenues from Soliris sales were unlikely to be sustainable; and (3) as a result, Alexion’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-991.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
